DAXOR CORP
Daxor Corporation (NYSE Amex: DAXO) operates as a medical device manufacturing company with biotechnology services, headquartered in New York. The company maintains its primary website at www.daxor.com and operates a subsidiary website at www.Idant.com for Scientific Medical Systems. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What DAXOR CORP does
In the company’s own words
Daxor Corporation (NYSE Amex: DAXO) operates as a medical device manufacturing company with biotechnology services, headquartered in New York. The company maintains its primary website at www.daxor.com and operates a subsidiary website at www.Idant.com for Scientific Medical Systems.
The company's core business centers on the BVA-100 Blood Volume Analyzer, a CLIA-rated instrument that measures human blood volume with 98% accuracy within 60 to 90 minutes. This device is used in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The BVA-100 addresses a significant clinical need, as traditional methods of blood volume measurement have been complex and time-consuming. The technology enables diagnosis and treatment of patients with heart failure, kidney failure, hypertension, syncope, and supports fluid and blood transfusion management in critical care settings. The company obtained FDA marketing clearance for the BVA-100 in 1997 and for Volumex in 1998, and holds United States, European Common Market, and Japanese patents for the technology.
Daxor operates the Daxor Oak Ridge Operations facility in Oak Ridge, Tennessee, which manufactures, tests, and develops next-generation models of the BVA-100. The company manufactures its own injection kit components and specialized collection kits, with injection kit filling performed by an FDA-licensed radiopharmaceutical manufacturer.
The company's wholly-owned subsidiary, Scientific Medical Systems, provides cryobanking services for blood storage and operates Idant Laboratories, which offers semen banking services. These operations represent a legacy business dating to the company's original incorporation as Iatric Corporation in 1971 for cryobanking services.
Daxor targets the approximately 8,500 hospitals and radiology imaging centers in the United States, with an additional international market of 10,000 to 14,000 potential users. The company has supported extensive clinical research, resulting in nineteen original research articles and seven review articles published since 2002 demonstrating the clinical applications of blood volume measurement. Blood volume measurement is an approved test with six separate CPT codes, and reimbursement has been obtained from numerous insurance companies, including Medicare.
Company details
- Sector
- Other
- Industry
- Other
- Headquarters
- OAK RIDGE, TN
- Fiscal year end
- December
- CIK
- 27367
Financial performance, year by year
Fiscal 2011–2011 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns DAXOR CORP — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · DAXOR CORP’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do DAXOR CORP and its peers compare on margins and cash generation over ten years?”
- “Where did five years of DAXOR CORP's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in DAXOR CORP's last four quarterly filings that the numbers alone won't show?”